The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

"Spravato" can be used on its own by people who don't respond to traditional depression medication. Against the odds, Prince ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

The Colorado House of Representatives has given its final approval to a bill that would allow a form of psilocybin to be prescribed as a medication if the federal government authorizes its use. About ...

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...

A Senate committee in Virginia has advanced legislation that would fund clinical trials involving veterans and “breakthrough therapies” as designated by the Food and Drug Administration (FDA), ...

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

The FDA's decision comes despite mixed results in clinical trials of the drug as an adjunctive treatment for depression. It comes on the back of a new pair of pivotal trials (RGH-MD-75 and 3111 ...